Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00453206 · ClinicalTrials.gov registry record · NA
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 66
- Enrollment target
NCT00453206 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 66 participants.
The verdict
NCT00453206, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
Study Summary
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and melphalan, before a donor peripheral stem cell transplant or bone marrow transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving tacrolimus, methotrexate, mycophenolate mofetil, and antithymocyte globulin before and after transplant may stop this from happening. Once the donated stem cells begin working, the patient's immune system may see the remaining cancer or abnormal cells as not belonging in the patient's body and destroy them (graft-versus-tumor effect). Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) may boost this effect. PURPOSE: This phase II trial is studying how well donor stem cell transplant works in treating patients with hematologic cancer or other diseases.
Interventions
- PROCEDURE allogeneic hematopoietic stem cell transplantation
- PROCEDURE peripheral blood stem cell transplantation
- PROCEDURE allogeneic bone marrow transplantation
- PROCEDURE nonmyeloablative allogeneic hematopoietic stem cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2007-02 |
| Est. Completion | 2014-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00453206
The ClinicalTrials.gov registry entry for NCT00453206 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which allogeneic hematopoietic stem cell transplantation is the first listed.
NCT00453206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00453206 about?
NCT00453206 is a clinical study titled "Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases". RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and melphalan, before a donor peripheral stem cell transplant or bone marrow transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the hea...
What is the current status of trial NCT00453206?
This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2007-02. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00453206?
The interventions under investigation include: allogeneic hematopoietic stem cell transplantation (PROCEDURE), peripheral blood stem cell transplantation (PROCEDURE), allogeneic bone marrow transplantation (PROCEDURE), nonmyeloablative allogeneic hematopoietic stem cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00453206?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.